small molecule

QUZYTTIR

CETIRIZINE HYDROCHLORIDE

Loss of exclusivityFebruary 2030latest FDA-listed patent expiry
CompanyEsteveSee this company's full patent-cliff portfolio

Drug detail

Brand nameQUZYTTIR
Active ingredientCETIRIZINE HYDROCHLORIDE
Strength10MG/ML (10MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalOctober 2019
Marketing statusRX

Listed patents

PatentExpiresType
8314083February 2030use U-2634
8263581February 2030use U-2635
9180090February 2030use U-2635
8513259February 2030use U-2636
9119771February 2030use U-2635

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

QUZYTTIR patent cliff — loss of exclusivity February 2030 | CliffBio